Anti-IL-27 antibodies and uses thereof

A method of stimulating an immune response or treating an IL-27-associated cancer in a human subject in need thereof comprising administering to the human subject an antibody that antagonizes human IL-27, or an antigen binding portion thereof, wherein the antibody or antigen binding portion thereof:

• specifically binds to an epitope comprising one or more amino acids of (i) amino acids 37 to 56 corresponding to SEQ ID NO:
• 2 (IL-27p28), (ii) amino acids 142 to 164 corresponding to SEQ ID NO:
• 2 (IL-27p28), or (iii) both (i) and (ii);
• comprises a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
• 119, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
• 120, a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
• 121, a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
• 127, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
• 128, and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
• 129;
• and
• is administered at a dose of about 10 mg/kg to about 20 mg/kg.